AbbVie Gets Expanded European Approvals for Skyrizi, Maviret
By Colin Kellaher
AbbVie has won expanded European Commission approvals for its blockbuster autoimmune drug Skyrizi and its hepatitis C drug Maviret.
AbbVie on Tuesday said Skyrizi is now approved in Europe for patients ages 6 and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Skyrizi was previously approved in Europe for adults with the chronic autoimmune disease.
The North Chicago, Ill., biopharmaceutical company said the new approval includes a new 55-milligram pre-filled syringe to support weight-based dosing for patients weighing less than 40 kilograms.
Separately, AbbVie said the EC approved Maviret for the treatment of acute hepatitis C virus infection in people ages 3 and older.
Maviret, which is sold in the U.S. as Mavyret, is now the only treatment approved in the European Union for both acute and chronic hepatitis C virus infection, AbbVie said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 23, 2026 06:35 ET (10:35 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States